Modafinil for daytime somnolence in Parkinson's disease : double blind, placebo controlled parallel trial
Identifieur interne : 001205 ( Main/Merge ); précédent : 001204; suivant : 001206Modafinil for daytime somnolence in Parkinson's disease : double blind, placebo controlled parallel trial
Auteurs : W Ondo [États-Unis] ; R Fayle [États-Unis] ; F Atassi [États-Unis] ; J Jankovic [États-Unis]Source :
- Journal of neurology, neurosurgery and psychiatry [ 0022-3050 ] ; 2005.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
Background: Excessive daytime somnolence (EDS) commonly complicates Parkinson's disease (PD). The aetiology of EDS is probably multifactorial but is probably exacerbated by dopaminergic medications. Modafinil is a wake-promoting agent approved for use in narcolepsy, but it is often used to treat a variety of somnolent conditions. Method: A double blind, placebo controlled parallel design trial was conducted to assess the efficacy of modafinil (200-400 mg/day) for the treatment of EDS in PD. The primary efficacy measure was the Epworth Sleepiness (ES) scale score. Secondary efficacy points included the Unified Parkinson's Disease Rating Scale (UPDRS), the Fatigue Severity Scale, the Hamilton Depression Scale, and the multiple sleep latency test (MSLT). Results: Of a total of 40 subjects (29 men, mean (SD) age 64.8 (11.3) years), randomised to modafinil or placebo, 37 completed the study. Modafinil failed to significantly improve ES scores compared with placebo (2.7 v 1.5 points improvement, respectively, p=0.28). MSLT failed to improve with modafinil relative to placebo (-0.16 v -0.70, respectively, p=0.14). UPDRS, global impressions, Fatigue Severity Scale, and Hamilton Depression Scale scores were unchanged. Adverse events were minimal. Conclusion: Modafinil failed to significantly improve EDS in PD compared with placebo. The drug did not alter motor symptoms in PD and was well tolerated.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000077
- to stream PascalFrancis, to step Curation: 000089
- to stream PascalFrancis, to step Checkpoint: 000085
Links to Exploration step
Pascal:06-0013786Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Modafinil for daytime somnolence in Parkinson's disease : double blind, placebo controlled parallel trial</title><author><name sortKey="Ondo, W G" sort="Ondo, W G" uniqKey="Ondo W" first="W" last="Ondo">W Ondo</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Baylor College of Medicine</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Fayle, R" sort="Fayle, R" uniqKey="Fayle R" first="R" last="Fayle">R Fayle</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Park Plaza Hospital</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Atassi, F" sort="Atassi, F" uniqKey="Atassi F" first="F" last="Atassi">F Atassi</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Baylor College of Medicine</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J Jankovic</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Baylor College of Medicine</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0013786</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 06-0013786 INIST</idno><idno type="RBID">Pascal:06-0013786</idno><idno type="wicri:Area/PascalFrancis/Corpus">000077</idno><idno type="wicri:Area/PascalFrancis/Curation">000089</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000085</idno><idno type="wicri:doubleKey">0022-3050:2005:Ondo W:modafinil:for:daytime</idno><idno type="wicri:Area/Main/Merge">001205</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Modafinil for daytime somnolence in Parkinson's disease : double blind, placebo controlled parallel trial</title><author><name sortKey="Ondo, W G" sort="Ondo, W G" uniqKey="Ondo W" first="W" last="Ondo">W Ondo</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Baylor College of Medicine</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Fayle, R" sort="Fayle, R" uniqKey="Fayle R" first="R" last="Fayle">R Fayle</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Park Plaza Hospital</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Atassi, F" sort="Atassi, F" uniqKey="Atassi F" first="F" last="Atassi">F Atassi</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Baylor College of Medicine</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J Jankovic</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Baylor College of Medicine</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Journal of neurology, neurosurgery and psychiatry</title><title level="j" type="abbreviated">J. neurol. neurosurg. psychiatry</title><idno type="ISSN">0022-3050</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of neurology, neurosurgery and psychiatry</title><title level="j" type="abbreviated">J. neurol. neurosurg. psychiatry</title><idno type="ISSN">0022-3050</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Modafinil</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Placebo</term><term>Somnolence</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term><term>Parkinson maladie</term><term>Modafinil</term><term>Somnolence</term><term>Placebo</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Excessive daytime somnolence (EDS) commonly complicates Parkinson's disease (PD). The aetiology of EDS is probably multifactorial but is probably exacerbated by dopaminergic medications. Modafinil is a wake-promoting agent approved for use in narcolepsy, but it is often used to treat a variety of somnolent conditions. Method: A double blind, placebo controlled parallel design trial was conducted to assess the efficacy of modafinil (200-400 mg/day) for the treatment of EDS in PD. The primary efficacy measure was the Epworth Sleepiness (ES) scale score. Secondary efficacy points included the Unified Parkinson's Disease Rating Scale (UPDRS), the Fatigue Severity Scale, the Hamilton Depression Scale, and the multiple sleep latency test (MSLT). Results: Of a total of 40 subjects (29 men, mean (SD) age 64.8 (11.3) years), randomised to modafinil or placebo, 37 completed the study. Modafinil failed to significantly improve ES scores compared with placebo (2.7 v 1.5 points improvement, respectively, p=0.28). MSLT failed to improve with modafinil relative to placebo (-0.16 v -0.70, respectively, p=0.14). UPDRS, global impressions, Fatigue Severity Scale, and Hamilton Depression Scale scores were unchanged. Adverse events were minimal. Conclusion: Modafinil failed to significantly improve EDS in PD compared with placebo. The drug did not alter motor symptoms in PD and was well tolerated.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Ondo, W G" sort="Ondo, W G" uniqKey="Ondo W" first="W" last="Ondo">W Ondo</name></region><name sortKey="Atassi, F" sort="Atassi, F" uniqKey="Atassi F" first="F" last="Atassi">F Atassi</name><name sortKey="Fayle, R" sort="Fayle, R" uniqKey="Fayle R" first="R" last="Fayle">R Fayle</name><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J Jankovic</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001205 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001205 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Main
|étape= Merge
|type= RBID
|clé= Pascal:06-0013786
|texte= Modafinil for daytime somnolence in Parkinson's disease : double blind, placebo controlled parallel trial
}}
| This area was generated with Dilib version V0.6.19. |  |